Document is current
Any future updates will be listed below
-
Authors
Marston, Nicholas A. https://orcid.org/0000-0001-6164-4617
Kany, Shinwan https://orcid.org/0000-0001-8113-733X
Melloni, Giorgio E. M. https://orcid.org/0000-0001-6371-1334
Jurgens, Sean J. https://orcid.org/0000-0002-1605-9782
Kamanu, Frederick K. https://orcid.org/0000-0001-7208-1047
Lai, Yi-Pin https://orcid.org/0000-0002-6550-8329
Rämö, Joel T. https://orcid.org/0000-0002-6429-5149
Raz, Itamar
Wiviott, Stephen D.
Ellinor, Patrick T.
Sabatine, Marc S.
Ruff, Christian T. https://orcid.org/0000-0002-4712-3206
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (521832260)
Hartstichting (03-007-2022-0035)
Foundation for the National Institutes of Health (1RO1HL092577, K24HL105780)
- License Information
-
More Information
Article History
Received: 11 September 2025
Accepted: 30 April 2026
First Online: 8 June 2026
Competing interests
: N.A.M. reports research grant support from the National Institutes of Health and involvement in clinical trials with Amgen, Ionis, Pfizer, Novartis, and AstraZeneca, consultant fees from Beckman Coulter, Cleerly, Inc. (CPC Clinical Research) and Viz.ai, and honoraria for lectures/CME Programs from Amgen, Illumina, and Medical Education Speakers Network (MESN). S.D.W. is an employee of the trial sponsor, AstraZeneca. P.T.E. receives sponsored research support from Bayer AG, Bristol Myers Squibb, Pfizer and Novo Nordisk; he has also served on advisory boards or consulted for Bayer AG. M.S.S. reports research grant support through Brigham and Women’s Hospital from Abbott, Amgen, Anthos Therapeutics, Inc., AstraZeneca, Beijing Inno Medicine, Boehringer Ingelheim, Daiichi Sankyo, Ionis, Marea, Merck, Novartis, Pfizer, Saghmos Therapeutics and Verve Therapeutics, and consulting for Amgen, AMPEL BioSolutions, Anthos Therapeutics, Inc., AstraZeneca, Beren Therapeutics, Boehringer Ingelheim, Dr. Reddy’s Laboratories, Fibrogen, General Medicines, Merck, Moderna, Novo Nordisk, Precision BioSciences, Silence Therapeutics and TigerMed. C.T.R. reports research grants through Brigham and Women’s Hospital from Anthos, AstraZeneca, Daiichi Sankyo, Janssen and Novartis and has received honoraria for scientific advisory boards and consulting from Anthos, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Janssen and Pfizer. Furthermore, N.A.M., G.E.M.M., F.K.K., Y.-P.L., M.S.S. and C.T.R. are members of the TIMI (Thrombolysis in Myocardial Infarction) Study Group, which has received institutional research grant support through Brigham and Women’s Hospital from Abbott, Abiomed, Inc., Amgen, Anthos Therapeutics, ARCA Biopharma, Inc., AstraZeneca, Boehringer Ingelheim, Cleerly, Inc., Daiichi Sankyo, Ionis Pharmaceuticals, Inc., Janssen Research and Development, LLC, MedImmune, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Roche, Saghmos Therapeutics, Inc., Softcell Medical Limited, The Medicines Company, Verve Therapeutics, Inc., and Zora Biosciences. The other authors declare no competing interests.
